Sweden’s Karo Pharma AB is poised to beef up its consumer health portfolio by acquiring a basket of brands from Denmark’s Leo Pharma AS for €90m ($101m). The transaction is expected to close during the first quarter of 2020, subject to regulatory approval.
Karo said the acquisition would strengthen its position in Europe, notably in the DACH region (Germany, Austria and Switzerland), and...